Final Results

BIOVENTIX PLC                                 

                 FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2010                 

                                2 NOVEMBER 2010                                

Chairman's and Chief Executive's Statement

The activities of the company remained largely unchanged during the financial
period. Resources continued to be focussed on the creation and supply of sheep
monoclonal antibodies for use on clinical diagnostics machines used at
hospitals, clinics and other laboratories. Such machines, provided by large
multinational diagnostics companies such as Roche Diagnostics (Mannheim),
Abbott Laboratories (Chicago), Siemens Healthcare Diagnostics (Deerfield) and
others, are used for the analysis of blood, urine and other samples from human
patients.

Over the last 12 months, the company has enjoyed a solid financial performance
with continued profitability and further strengthening of the balance sheet.
Revenues from the supply of purified antibodies together with royalty payments
derived from the sale of certain tests that feature Bioventix antibodies have
been roughly even.

Your attention is drawn to restatement of the results for the year ended 30
June 2009 which arises from a cumulative prior year adjustment of £369,728 in
respect of the accounting treatment of convertible loan notes. These loan notes
were converted in the year ended 30 June 2010 and this resulted in an
adjustment via reserves during the year.

The financial performance over the near future is expected to improve modestly
as income from new tests featuring Bioventix antibodies (eg for Estradiol and
testosterone) reach the market and royalty payments start to flow from these
advanced projects.

A major part of the company's research over the past two years has focussed on
the creation of antibodies to vitamin D. There is a high level of interest
within the medical community in testing for vitamin D (specifically 25-hydroxy
vitamin Ds) levels in patients, as a result of growing evidence of the
importance that this vitamin has in various areas of human health. Hence, there
is interest amongst Bioventix customers in antibodies that can be used in such
tests. This research has yielded interesting internal data on the Bioventix
vitamin D antibody portfolio, and one antibody in particular called vitD3.5H10
has exciting potential. A clearer picture of the utility of vitD3.5H10 will not
emerge until further customer feedback is obtained during 2011.

The substantial progress of Bioventix during the period is due above all to the
contributions of its employees and their commitment to Bioventix's future. On
behalf of the Board, we would like to thank them for their efforts which have
underpinned our success.

On 15 March 2010 Bioventix Limited re-registered as a Plc and hence is now
known as Bioventix plc. Bioventix plc is now trading on PLUSMarket, and was
quoted from April 2010. This resulted in a one off cost of £95,844.


P J Harrison
Chief Executive Officer

I J Nicholson
Non-Executive Chairman

For further information, please contact:

Bioventix plc
Peter Harrison
Tel: [phone]

Keith, Bayley, Rogers & Co. Limited
David Coffman
Tel: [phone]

About Bioventix plc

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies.

Bioventix is based in Farnham, UK and its shares (BVXP) were admitted to
trading on PLUS-quoted in April 2010.

                     PUBLICATION OF NON-STATUTORY ACCOUNTS                     

The financial information set out in this announcement does not constitute
statutory financial statements for the year ended 30 June 2010 or 30 June 2009.
The reports of the auditor on the statutory financial statements for each of
the years ended 30 June 2010 and 30 June 2009 were (i) unqualified; (ii) did
not include references to any matters to which the auditor drew attention by
way of emphasis without qualifying their report; and (iii) did not contain
statements under section 498(2) or (3) of the Companies Act 2006. The statutory
financial statements for the year ended 30 June 2009 have been delivered to the
Registrar of Companies. The statutory financial statements for the year ended
30 June 2010 will be delivered to the Registrar of Companies following the
Company's Annual General Meeting

                            PROFIT AND LOSS ACCOUNT                            

                        FOR THE YEAR ENDED 30 JUNE 2010                        

                                                             2010          2009
                                                                               
                                                                £             £
                                                                  (as restated)
                                                                               
TURNOVER                                                1,578,162     1,647,679
                                                                               
Cost of sales                                           (197,309)     (160,356)
                                                                               
GROSS PROFIT                                            1,380,853     1,487,323
                                                                               
Administrative expenses                                 (605,782)     (503,259)
                                                                               
Exceptional costs of listing on PLUS Market              (95,844)             -
                                                                               
Total administrative expenses                           (701,626)     (503,259)
                                                                               
Other operating income                                         75           100
                                                                               
OPERATING PROFIT                                          679,302       984,164
                                                                               
Interest receivable                                         3,404        13,897
                                                                               
Interest payable                                                -     (140,981)
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE                      682,706       857,080
TAXATION                                                                       
                                                                               
Tax on profit on ordinary activities                    (118,285)     (221,164)
                                                                               
PROFIT FOR THE FINANCIAL YEAR                             564,421       635,916
                                                                               

Earnings per share

Basic 11.37p (2009:12.91p)
Diluted 11.37p (2009:12.59p)

All amounts relate to continuing operations.


There were no recognised gains and losses for 2010 or 2009 other than those
included in the Profit and loss account.


                                 BALANCE SHEET                                 

                              AS AT 30 JUNE 2010                               

                                                     2010                   2009  
                                                                                
                                             £          £          £           £
                                                                    (as restated)
                                                                                
FIXED ASSETS                                                                    
                                                                                
Intangible fixed assets                            70,000                 90,000
                                                                                
Tangible fixed assets                             463,690                460,028
                                                                                
                                                  533,690                550,028
                                                                                
CURRENT ASSETS                                                                  
                                                                                
Stocks                                  90,175                118,899           
                                                                                
Debtors                                573,992                525,359           
                                                                                
Cash at bank and in hand             1,349,084              1,184,471           
                                                                                
                                     2,013,251              1,828,729           
                                                                                
CREDITORS: amounts falling due       (173,992)            (1,442,989)           
within one year                                                                 
                                                                                
NET CURRENT ASSETS                              1,839,259                385,740
                                                                                
TOTAL ASSETS LESS CURRENT LIABILITIES           2,372,949                935,768
                                                                                
PROVISIONS FOR LIABILITIES                                                      
                                                                                
Deferred Tax                                      (7,173)               (85,349)
                                                                                
NET ASSETS                                      2,365,776                850,419
                                                                                
CAPITAL AND RESERVES                                                            
                                                                                
Called up share capital                           252,500                  3,850
                                                                                
Share premium account                                   -                166,681
                                                                                
Other reserves                                          -                369,728
                                                                                
Profit and loss account                         2,113,276                310,160
                                                                                
SHAREHOLDERS' FUNDS                             2,365,776                850,419

                              CASH FLOW STATEMENT                              

                        FOR THE YEAR ENDED 30 JUNE 2010                        

                                                             2010          2009
                                                                               
                                               Note             £             £
                                                                  (as restated)
                                                                               
Net cash flow from operating activities                   640,965       867,289
                                                                               
Returns on investments and servicing of                  (94,096)        13,897
finance                                                                        
                                                                               
Taxation                                                (149,195)      (60,870)
                                                                               
Capital expenditure and financial investment             (31,061)       (7,346)
                                                                               
Equity dividends paid                                   (202,000)      (58,500)
                                                                               
CASH INFLOW BEFORE FINANCING                              164,613       754,470
                                                                               
Financing                                                       -        17,143
                                                                               
INCREASE IN CASH IN THE YEAR                              164,613       771,613

         RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS/DEBT         

                        FOR THE YEAR ENDED 30 JUNE 2010                        

                                                             2010          2009
                                                                               
                                                                £             £
                                                                               
Increase in cash in the year                              164,613       771,613
                                                                               
CHANGE IN NET DEBT RESULTING FROM CASH FLOWS              164,613       771,613
                                                                               
Debt converted to equity                                1,071,438             -
                                                                               
Finance charge added to debt                                    -      (43,481)
                                                                               
MOVEMENT IN NET DEBT IN THE YEAR                        1,236,051       728,132
                                                                               
Net funds/(debt) at 1 July 2009                           113,033     (615,099)
                                                                               
NET FUNDS AT 30 JUNE 2010                               1,349,084       113,033

The Directors of Bioventix plc accept responsibility for this announcement.